US OptionsDetailed Quotes
JSPR241220C30000
- 0.85
- 0.000.00%
15min DelayClose Nov 27 16:00 ET
0.00High0.00Low
0.85Open0.85Pre Close0 Volume52 Open Interest30.00Strike Price0.00Turnover122.06%IV32.75%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier21DDays to Expiry0.85Extrinsic Value100Contract SizeAmericanOptions Type0.2406Delta0.0452Gamma27.34Leverage Ratio-0.0505Theta0.0028Rho6.58Eff Leverage0.0176Vega
Jasper Therapeutics Stock Discussion
Sign in to post a comment
$Jasper Therapeutics (JSPR.US)$ good time to hop in
$Destiny Tech100 (DXYZ.US)$ $Vanda Pharmaceuticals (VNDA.US)$ $In8bio (INAB.US)$ $Rani Therapeutics (RANI.US)$ $Jasper Therapeutics (JSPR.US)$ $B Riley Financial Inc 7.5% Sr Nts 31/05/2027 Usd25 (RILYZ.US)$ $B. Riley Financial Inc (RILYP.US)$ $B Riley Financial Inc 6.375% Senior Notes Due 2025 (RILYM.US)$ $B. Riley Financial (RILY.US)$ $Longboard Pharmaceuticals (LBPH.US)$ $Expion360 (XPON.US)$ $Inventiva (IVA.US)$ $Tevogen Bio Holdings (TVGN.US)$
1
$Jasper Therapeutics (JSPR.US)$
Jasper Therapeutics Reports Positive Data from SPOTLIGHT Study of Briquilimab in Chronic Inducible Urticaria
14 of 15 participants enrolled achieved a clinical response
10 of 12 participants in the 120mg cohort achieved a complete response
No serious adverse events; no grade 3 or higher adverse events reported
Initial data from BEACON study expected week of January 6th, 2025, including 180mg Q8W cohort
Company to host conference call and webinar today at 8:00 ...
Jasper Therapeutics Reports Positive Data from SPOTLIGHT Study of Briquilimab in Chronic Inducible Urticaria
14 of 15 participants enrolled achieved a clinical response
10 of 12 participants in the 120mg cohort achieved a complete response
No serious adverse events; no grade 3 or higher adverse events reported
Initial data from BEACON study expected week of January 6th, 2025, including 180mg Q8W cohort
Company to host conference call and webinar today at 8:00 ...
$Jasper Therapeutics (JSPR.US)$ hmmmm, reverse split tomorrow and then gets halted 10 minutes before close pending news. interesting
The application scenarios related to multi-modal large models will gradually become popular with the improvement of significant model capabilities and cost reduction. The US stock market recommends paying attention to the following:
Microsoft $Microsoft (MSFT.US)$ (office currently has nearly 400 million users, OficARPU increases after the acquisition of OpenA and Azurez-related...
Microsoft $Microsoft (MSFT.US)$ (office currently has nearly 400 million users, OficARPU increases after the acquisition of OpenA and Azurez-related...
5
$Jasper Therapeutics (JSPR.US)$ look how close the 5, 10, 20 & 30 day moving avergaes are on daily scale. To be honest, I don’t think I’ve seen a Stock like this before that has run 350% in one day consolidate to such tight parameters. Hopefully the price remains a current level or higher at open tomorr...
5
11
No comment yet
Kamacho09 OP : Shoulda bought more at 15